The long-term effect of ursodeoxycholic acid on laboratory liver parameters in biochemically non-advanced primary biliary cirrhosis;Effet à long terme de l'acide ursodésoxycholique sur les test biochimiques hépatiques dans la cirrhose biliaire primitive

Clinics and Research in Hepatology and Gastroenterology

Volumn 35, Issue 1, 2011, Pages 29-33

  Kuiper, E M M ^a   Hansen, B E ^a   Lesterhuis, W ^b   Robijn, R J ^c   Thijs, J C ^d   Engels, L G J B ^e   Koek, G H ^f   Aparicio, M N ^g   Kerbert Dreteler, M J ^h   Van Buuren, H R ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b ALBERT SCHWEITZER HOSPITAL   (Netherlands)

^c RIJNSTATE HOSPITAL   (Netherlands)

^d Bethesda Hospital   (Netherlands)

^e Zuyderland Medical Centre   (Netherlands)

^f MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^g CANISIUS WILHELMINA HOSPITAL   (Netherlands)

^h MEDISCH SPECTRUM TWENTE   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; ALKALINE PHOSPHATASE; AMINOTRANSFERASE; BILIRUBIN; IMMUNOGLOBULIN M; URSODEOXYCHOLIC ACID;

ADULT; AGED; ALBUMIN BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; BILIRUBIN BLOOD LEVEL; BIOCHEMISTRY; COHORT ANALYSIS; CONTROLLED STUDY; DATA ANALYSIS; DRUG EFFECT; DRUG RESPONSE; FEMALE; FOLLOW UP; HUMAN; IMMUNOGLOBULIN BLOOD LEVEL; LIVER FUNCTION; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PRIMARY BILIARY CIRRHOSIS; PROSPECTIVE STUDY;

CHOLAGOGUES AND CHOLERETICS; FEMALE; HUMANS; LIVER; LIVER CIRRHOSIS, BILIARY; LIVER FUNCTION TESTS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; TIME FACTORS; URSODEOXYCHOLIC ACID;

EID: 79955992671     PISSN: 22107401     EISSN: 2210741X     Source Type: Journal    
DOI: 10.1016/j.gcb.2010.07.018     Document Type: Article

References (18)

1. EASL Clinical Practice Guidelines: management of cholestatic liver diseases. J Hepatol 2009;51(2):237-67.
2. Lindor K.D., Gershwin M.E., Poupon R., Kaplan M., Bergasa N.V., Heathcote E.J. Primary biliary cirrhosis. Hepatology 2009, 50(1):291-308.
3. Leuschner U., Guldutuna S., Imhof M., Hubner K., Benjaminov A., Leuschner M. Effects of ursodeoxycholic acid after 4 to 12 years of therapy in early and late stages of primary biliary cirrhosis. J Hepatol 1994, 21(4):624-633.
4. Van Hoogstraten H.J., Hansen B.E., van Buuren H.R., ten Kate F.J., van Berge-Henegouwen G.P., Schalm S.W., et al. Prognostic factors and long-term effects of ursodeoxycholic acid on liver biochemical parameters in patients with primary biliary cirrhosis. J Hepatol 1999, 31(2):256-262.
5. Kuiper E.M., Hansen B.E., de Vries R.A., Den Ouden-Muller J.W., van Ditzhuijsen T.J., Haagsma E.B., et al. Improved prognosis of patients with primary biliary cirrhosis that have a biochemical response to ursodeoxycholic acid. Gastroenterology 2009, 136(4):1281-1287.
6. Pares A., Caballeria L., Rodes J., Bruguera M., Rodrigo L., Garcia-Plaza A., et al. Long-term effects of ursodeoxycholic acid in primary biliary cirrhosis: results of a double-blind controlled multicentric trial. UDCA-Cooperative Group from the Spanish Association for the Study of the Liver. J Hepatol 2000, 32(4):561-566.
7. Corpechot C., Abenavoli L., Rabahi N., Chretien Y., Andreani T., Johanet C., et al. Biochemical response to ursodeoxycholic acid and long-term prognosis in primary biliary cirrhosis. Hepatology 2008, 48(3):871-877.
8. Taal B.G., Schalm S.W., ten Kate F.W., Hermans J., Geertzen R.G., Feltkamp B.E. Clinical diagnosis of primary biliary cirrhosis: a classification based on major and minor criteria. Hepatogastroenterology 1983, 30(5):178-182.
9. Ludwig J., Dickson E.R., McDonald G.S. Staging of chronic nonsuppurative destructive cholangitis (syndrome of primary biliary cirrhosis). Virchows Arch A Pathol Anat Histol 1978, 379(2):103-112.
10. Van Hoogstraten H.J., De Smet M.B., Renooij W., Breed J.G., Engels L.G., Den Ouden-Muller J.W., et al. A randomized trial in primary biliary cirrhosis comparing ursodeoxycholic acid in daily doses of either 10mg/kg or 20mg/kg. Aliment Pharmacol Ther 1998, 12(10):965-971.
11. Poupon R.E., Balkau B., Eschwege E., Poupon R., UDCA-PBC Study Group A multicenter, controlled trial of ursodiol for the treatment of primary biliary cirrhosis. N Engl J Med 1991, 324(22):1548-1554.
12. Leuschner M. UDCA, PBC, and biochemistry, what does normal mean?. Gut 2000, 47(4):595-596.
13. Nyblom H., Bjornsson E., Simren M., Aldenborg F., Almer S., Olsson R. The AST/ALT ratio as an indicator of cirrhosis in patients with PBC. Liver Int 2006, 26(7):840-845.
14. ter Borg P.C., Schalm S.W., Hansen B.E., van Buuren H.R. Prognosis of ursodeoxycholic Acid-treated patients with primary biliary cirrhosis. Results of a 10-yr cohort study involving 297 patients. Am J Gastroenterol 2006, 101(9):2044-2050.
15. Angulo P., Keach J.C., Batts K.P., Lindor K.D. Independent predictors of liver fibrosis in patients with nonalcoholic steatohepatitis. Hepatology 1999, 30(6):1356-1362.
16. Pohl A., Behling C., Oliver D., Kilani M., Monson P., Hassanein T. Serum aminotransferase levels and platelet counts as predictors of degree of fibrosis in chronic hepatitis C virus infection. Am J Gastroenterol 2001, 96(11):3142-3146.
17. Corpechot C., Carrat F., Poupon R., Poupon R.E. Primary biliary cirrhosis: incidence and predictive factors of cirrhosis development in ursodiol-treated patients. Gastroenterology 2002, 122(3):652-658.
18. Kikuchi K., Hsu W., Hosoya N., Moritoki Y., Kajiyama Y., Kawai T., et al. Ursodeoxycholic acid reduces CpG-induced IgM production in patients with primary biliary cirrhosis. Hepatol Res 2009, 39(5):448-454.